Logo

Zevra Therapeutics, Inc.

ZVRA

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disea… read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.85

Price

+2.55%

$0.22

Market Cap

$498.210m

Small

Price/Earnings

18.8x

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

+5.6%

EBITDA Margin

-5.4%

Net Profit Margin

+15.9%

Free Cash Flow Margin

+5.6%

EBITDA Margin

-5.4%

Net Profit Margin

+15.9%

Free Cash Flow Margin
Revenue

$84.388m

+257.4%

1y CAGR

+137.9%

3y CAGR

+87.3%

5y CAGR
Earnings

$34.459m

+132.7%

1y CAGR

-22.8%

3y CAGR

-70.3%

5y CAGR
EPS

$0.63

+127.6%

1y CAGR

-4.8%

3y CAGR

+12.2%

5y CAGR
Book Value

$133.165m

$270.116m

Assets

$136.951m

Liabilities

$62.717m

Debt
Debt to Assets

23.2%

0.9x

Debt to EBITDA
Free Cash Flow

-$24.230m

+65.2%

1y CAGR

-40.2%

3y CAGR

-100.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases